Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]-AraG PET Imaging in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07168785Phase 1Not yet recruiting
- Sponsor
- Indiana University
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorine f 18 ara-g in head and neck squamous cell carcinoma (HNSCC), sponsored by Indiana University. Primary endpoints: [18F]-AraG PET/CT uptake and infiltrating cytotoxic T-cell expression at 16 weeks, Pre-treatment [18F]-AraG PET/CT uptake and clinical response at 0 weeks and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
fluorine f 18 ara-g
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07168785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168785.